Zealand Pharma A/S (0NZU.L)
- Previous Close
118.72 - Open
123.20 - Bid --
- Ask --
- Day's Range
123.20 - 124.50 - 52 Week Range
123.20 - 124.50 - Volume
11,884 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
www.zealandpharma.com253
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0NZU.L
Performance Overview: 0NZU.L
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0NZU.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0NZU.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-205.30%
Return on Assets (ttm)
-19.93%
Return on Equity (ttm)
-58.43%
Revenue (ttm)
342.79M
Net Income Avi to Common (ttm)
-703.74M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.63B
Total Debt/Equity (mrq)
7.49%
Levered Free Cash Flow (ttm)
-228.98M